Company / Net Income
Olema Pharmaceuticals, Inc. Net Income History
FY2019-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$129.5M
FY2024
5-year range
-$129.5M / -$22.1M
FY2020-FY2024
Trend
-34.0%
vs FY2023
Sector context
#118 of 216
Health Care
What the data says
At -$129M, Olema Pharmaceuticals, Inc.'s net income ranks #118 of 216 in the Health Care sector. Declined from -$105M to -$129M over the past 2 years.
Based on SEC 10-K filings.
-$129M in FY2024.
Declined from -$105M to -$129M over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#118 of 216 in Health CareTop 55% of 216This company -$129.5M Sector average $454.3M
▼
-128.5% below sector average
Key checks
Key Insights
- In FY2024, net income decreased 34.0% year-over-year.
- Ranks #118 out of 216 companies in the Health Care sector.
- Peak net income was recorded in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.74 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$129.5M | -34.0% |
| FY2023 | -$96.7M | +7.8% |
| FY2022 | -$104.8M | -47.4% |
| FY2021 | -$71.1M | -221.4% |
| FY2020 | -$22.1M | -412.5% |
| FY2019 | -$4.3M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026